See more : Zhejiang Huakang Pharmaceutical Co., Ltd. (605077.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Merrimack Pharmaceuticals, Inc. (MACK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Merrimack Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- SSC Security Services Corp. (SECU.V) Income Statement Analysis – Financial Results
- Eastfield Resources Ltd. (ETFLF) Income Statement Analysis – Financial Results
- Anhui Huilong Agricultural Means of Production Co.,Ltd. (002556.SZ) Income Statement Analysis – Financial Results
- Sung Gang Corp.Limited (6240.TWO) Income Statement Analysis – Financial Results
- Australian Agricultural Company Limited (AAC.AX) Income Statement Analysis – Financial Results
Merrimack Pharmaceuticals, Inc. (MACK)
About Merrimack Pharmaceuticals, Inc.
Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 144.27M | 89.26M | 102.76M | 47.79M | 48.92M | 34.22M | 20.31M | 2.15M |
| Cost of Revenue | 0.00 | 445.00K | 0.00 | 0.00 | 2.23M | 0.00 | 0.00 | 6.91M | 46.00K | 0.00 | 0.00 | 0.00 | 100.63M | 58.28M | 37.66M |
| Gross Profit | 0.00 | -445.00K | 0.00 | 0.00 | -2.23M | 0.00 | 0.00 | 137.36M | 89.21M | 102.76M | 47.79M | 48.92M | -66.42M | -37.97M | -35.51M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 95.21% | 99.95% | 100.00% | 100.00% | 100.00% | -194.11% | -187.01% | -1,653.17% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 11.10M | 49.97M | 67.31M | 160.92M | 160.99M | 138.50M | 147.14M | 125.86M | 365.00K | 0.00 | 0.00 |
| General & Administrative | 2.18M | 2.17M | 2.62M | 5.01M | 16.17M | 15.60M | 28.45M | 0.00 | 0.00 | 30.52M | 21.19M | 15.81M | 8.84M | 0.00 | 0.00 |
| Selling & Marketing | 2.17M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.62M | 0.00 | 0.00 |
| SG&A | 2.18M | 2.17M | 2.62M | 5.01M | 16.17M | 15.60M | 28.45M | 80.73M | 57.60M | 30.52M | 21.19M | 15.81M | 14.45M | 11.38M | 12.18M |
| Other Expenses | 0.00 | 0.00 | 0.00 | -191.00K | 370.00K | -3.23M | -1.43M | -43.38M | -18.22M | -17.30M | -10.15M | 988.00K | 34.16M | 0.00 | 0.00 |
| Operating Expenses | 2.18M | 2.17M | 2.62M | 5.01M | 27.27M | 65.58M | 95.77M | 241.65M | 218.58M | 169.01M | 168.33M | 141.66M | 14.45M | 11.38M | 12.18M |
| Cost & Expenses | 2.18M | 2.17M | 2.62M | 5.01M | 27.27M | 65.58M | 95.77M | 248.56M | 218.63M | 169.01M | 168.33M | 141.66M | 115.08M | 69.66M | 49.84M |
| Interest Income | 868.00K | 188.00K | 20.00K | 50.00K | 777.00K | 1.30M | 895.00K | 276.00K | 99.00K | 114.00K | 166.00K | 184.00K | 56.00K | 74.00K | 81.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 1.53M | 956.00K | 34.65M | 43.65M | 19.23M | 18.23M | 10.94M | 553.00K | 13.00K | 3.73M | 4.91M |
| Depreciation & Amortization | 167.90K | -890.00K | -288.00K | -2.28M | -1.54M | 4.07M | 5.22M | 6.25M | 4.29M | 3.22M | 2.59M | 3.66M | 5.33M | 4.38M | 2.76M |
| EBITDA | -2.18M | -2.62M | -2.76M | -5.15M | -20.26M | -65.58M | -91.08M | -110.14M | -125.28M | -66.26M | -120.54M | -92.74M | -75.49M | -44.90M | -44.85M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -68.22% | -144.94% | -64.48% | -252.25% | -189.58% | -220.63% | -221.13% | -2,088.08% |
| Operating Income | -2.18M | -1.73M | -2.47M | -2.87M | -22.36M | -65.58M | -95.77M | -110.14M | -129.57M | -66.26M | -120.54M | -92.74M | -80.87M | -49.18M | -47.69M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -76.34% | -145.16% | -64.48% | -252.25% | -189.58% | -236.36% | -242.19% | -2,220.11% |
| Total Other Income/Expenses | 1.01M | 188.00K | 20.00K | -141.00K | -381.00K | -2.89M | -22.64M | -43.38M | -18.22M | -17.30M | -10.15M | 1.47M | 1.19M | -983.00K | -4.79M |
| Income Before Tax | -1.17M | -1.54M | -2.45M | -3.01M | -22.74M | -68.46M | -118.40M | -153.52M | -147.79M | -83.56M | -130.69M | -91.75M | -79.68M | -50.16M | -52.48M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -106.41% | -165.57% | -81.32% | -273.48% | -187.56% | -232.87% | -247.03% | -2,442.97% |
| Income Tax Expense | 12.00K | 3.00K | 3.00K | 14.00K | -1.47M | -7.70M | -42.40M | -13.22M | -3.92M | -3.49M | -2.35M | -4.14M | -440.00K | 3.67M | -3.40M |
| Net Income | -1.18M | -1.54M | -2.46M | -3.03M | -21.27M | -40.51M | 472.03M | -151.74M | -147.96M | -83.29M | -130.93M | -91.28M | -79.22M | -50.10M | -49.07M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -105.18% | -165.76% | -81.06% | -273.98% | -186.58% | -231.54% | -246.76% | -2,284.59% |
| EPS | -0.08 | -0.11 | -0.18 | -0.23 | -1.59 | -3.04 | 35.67 | -12.11 | -13.29 | -7.98 | -13.24 | -12.53 | -8.57 | -44.17 | -43.26 |
| EPS Diluted | -0.08 | -0.11 | -0.18 | -0.23 | -1.59 | -3.04 | 35.67 | -12.11 | -13.29 | -7.98 | -13.24 | -12.53 | -8.57 | -44.17 | -43.26 |
| Weighted Avg Shares Out | 14.30M | 13.52M | 13.41M | 13.38M | 13.35M | 13.34M | 13.23M | 12.53M | 11.14M | 10.44M | 9.89M | 7.28M | 9.24M | 1.13M | 1.13M |
| Weighted Avg Shares Out (Dil) | 14.30M | 13.52M | 13.41M | 13.38M | 13.35M | 13.34M | 13.23M | 12.53M | 11.14M | 10.44M | 9.89M | 7.28M | 9.24M | 1.13M | 1.13M |
The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 19.) Biomerica, Inc. (NASDAQ...
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18) Biomerica, Inc. (NASDAQ: BMRA )( announced commencement of international shipment of rapid COVID-19 test)...
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18) Biomerica, Inc. (NASDAQ...
The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 17) …
The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) Masimo...
The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 11) Bicycle Therapeutics...
The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 11) Bicycle Therapeutics...
The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Feb. 26.) Co-Diagnostics Inc (NASDAQ: CODX ) Fate Therapeutics Inc (NASDAQ: FATE )...
The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 15) 10X Genomics Inc (NASDAQ...
The Daily Biotech Pulse: Axovant Surges On Gene Therapy Study Results, FDA Approves Merck's Ebola Vaccine, Abeona Announces Offering
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 19.) Acceleron Pharma Inc (NASDAQ: XLRN ) Ardelyx Inc (NASDAQ: ARDX ) AstraZeneca...
Source: https://incomestatements.info
Category: Stock Reports